B
Benji T. Kurian
Researcher at University of Texas Southwestern Medical Center
Publications - 53
Citations - 2955
Benji T. Kurian is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Major depressive disorder & Randomized controlled trial. The author has an hindex of 26, co-authored 53 publications receiving 2355 citations. Previous affiliations of Benji T. Kurian include University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression
Jaskaran Singh,Maggie Fedgchin,Ella J. Daly,Peter de Boer,Kimberly Cooper,Pilar Lim,Christine Pinter,James W. Murrough,Gerard Sanacora,Richard C. Shelton,Benji T. Kurian,Andrew Winokur,Maurizio Fava,Husseini K. Manji,Wayne C. Drevets,Luc Van Nueten +15 more
TL;DR: In this paper, the efficacy of twice and thrice-weekly intravenous administration of ketamine in sustaining initial antidepressant effects in patients with treatment-resistant depression was evaluated in a multicenter, double-blind study, where adults (ages 18-64 years) with treatmentresistant depression were randomized to receive either intravenous ketamine (0.5 mg/kg of body weight) or intravenous placebo, administered over 40 minutes, either two or three times weekly, for up to 4 weeks.
Journal ArticleDOI
Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study
A. John Rush,Madhukar H. Trivedi,Jonathan W. Stewart,Andrew A. Nierenberg,Maurizio Fava,Benji T. Kurian,Diane Warden,David W. Morris,James F. Luther,Mustafa M. Husain,Ian A. Cook,Richard C. Shelton,Ira M. Lesser,Susan G. Kornstein,Stephen R. Wisniewski +14 more
TL;DR: Two antidepressant medication combinations were compared with selective serotonin reuptake inhibitor monotherapy to determine whether either combination produced a higher remission rate in first-step acute-phase (12 weeks) and long-term (7 months) treatment.
Journal ArticleDOI
Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design.
Madhukar H. Trivedi,Patrick J. McGrath,Maurizio Fava,Ramin V. Parsey,Benji T. Kurian,Mary L. Phillips,Maria A. Oquendo,Gerard E. Bruder,Diego A. Pizzagalli,Marisa Toups,Crystal Cooper,Phil Adams,Sarah Weyandt,David W. Morris,Bruce D. Grannemann,R. Todd Ogden,Randy L. Buckner,Melvin G. McInnis,Helena C. Kraemer,Eva Petkova,Thomas J. Carmody,Myrna M. Weissman +21 more
TL;DR: The study is designed to standardize assessment of biomarkers across multiple sites as well as institute replicable quality control methods, and to use advanced data analytic methods to integrate these markers.
Journal ArticleDOI
Defining and measuring functional recovery from depression.
TL;DR: Clinicians and researchers alike need to broaden the focus of treatment to encompass not only the specific symptoms of depression, but the functional consequences as well.
Journal ArticleDOI
Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study
A. John Rush,Madhukar H. Trivedi,Jonathan W. Stewart,Andrew A. Nierenberg,Maurizio Fava,Benji T. Kurian,Diane Warden,David W. Morris,James F. Luther,Mustafa M. Husain,Ian A. Cook,Richard C. Shelton,Ira M. Lesser,Susan G. Kornstein,Stephen R. Wisniewski +14 more
TL;DR: Two antidepressant medication combinations were compared with selective serotonin reuptake inhibitor monotherapy to determine whether either combination produced a higher remission rate in first-step acute-phase (12 weeks) and long-term (7 months) treatment.